EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2023

Summary

Non-Hodgkin’s lymphoma (NHL) refers to a group of cancers that develop in the lymphatic system. In NHL, the body’s immune system is affected by the uncontrollable growth of malignant white blood cells, resulting in the body’s inability to fight infections and other diseases. NHL is characterized into three types - B-cell, T-cell, and natural killer lymphocyte lymphomas. B-cell lymphomas are the most common form of NHL in developed countries. NHL ranks as the most commonly occurring hematologic cancer in adults. Despite the many advances in research, NHL remains largely incurable and the causes unknown.

GlobalData epidemiologists forecast an increase in the incident cases of B-cell NHL in the 6MM, from 89,455 incident cases in 2013 to 111,366 incident cases in 2023, with an annual growth rate (AGR) of 2.45%. In 2023, the US will have the highest number of incident cases of B-cell NHL, with 56,033 incident cases, followed by Germany with 17,176 incident cases, and the UK with 12,548 incident cases.

For this analysis, GlobalData epidemiologists utilized peer-reviewed journals and country-specific disease databases to construct the 10-year epidemiological forecast for the incident cases of follicular lymphoma, marginal zone lymphoma, DLBCL, and mantle cell lymphoma in the 6MM. A major strength of GlobalData’s epidemiological analysis is the use of available country-specific sources, allowing for a meaningful comparison of the epidemiological characteristics of B-cell NHL in the 6MM. In addition, this forecast provides detailed segmentation of the B-cell NHL for each country by age, sex, and B-cell NHL subtype, thereby providing a comprehensive view of B-cell NHL in the 6MM.

Scope

- The Non-Hodgkin’s Lymphoma (NHL) EpiCast Report provides an overview of the risk factors, comorbidities, and global and historical epidemiological trends for NHL in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). It includes a 10-year epidemiological forecast of the incident cases of follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma [DLBCL], and mantle cell lymphoma segmented by age (ages =30 years) and sex in these markets.
- The NHL epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global NHL market.

- Quantify patient populations in the global NHL market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for NHL therapeutics in each of the markets covered.

Table Of Contents

1 Table of Contents

2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 9
3.3 Global Trends 12
3.3.1 US 12
3.3.2 5EU 13
3.4 Forecast Methodology 16
3.4.1 Sources Used 18
3.4.2 Sources Not Used 20
3.4.3 Forecast Assumptions and Methods 21
3.4.4 Age-Standardized Incidence Rates 24
3.5 Epidemiological Forecast of B-Cell NHL (2013-2023) 25
3.5.1 Follicular Lymphoma 25
3.5.2 Marginal Zone Lymphoma 30
3.5.3 DLBCL 36
3.5.4 Mantle Cell Lymphoma 42
3.6 Discussion 48
3.6.1 Epidemiological Forecast Insight 48
3.6.2 Limitations of the Analysis 48
3.6.3 Strengths of the Analysis 49
4 Appendix 50
4.1 Bibliography 50
4.2 About the Authors 54
4.2.1 Epidemiologists 54
4.2.2 Reviewers 54
4.2.3 Global Director of Epidemiology 55
4.2.4 Global Head of Healthcare 56
4.3 About GlobalData 57
4.4 About EpiCast 57
4.5 Disclaimer 58

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for NHL 11
Table 2: US, Age- and Sex-Specific Incidence of B-Cell NHL during 2001-2010 13
Table 3: 6MM, Sources of B-Cell NHL Incidence Data 17
Table 4: 6MM, Incident Cases of Follicular Lymphoma, Ages ?30 Years, Both Sexes, N, Selected Years 2013-2023 25
Table 5: 6MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N (Row %), 2013 27
Table 6: 6MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ?30 Years, N (Row %), 2013 28
Table 7: 6MM, Incident Cases of Marginal Zone Lymphoma, Ages ?30 Years, Both Sexes, N, Selected Years 2013-2023 31
Table 8: 6MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N (Row %), 2013 32
Table 9: 6MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ?30 Years, N (Row %), 2013 34
Table 10: 6MM, Incident Cases of DLBCL, Ages ?30 Years, Both Sexes, N, Selected Years 2013-2023 37
Table 11: 6MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N (Row %), 2013 38
Table 12: 6MM, Sex-Specific Incident Cases of DLBCL, Ages ?30 Years, N (Row %), 2013 40
Table 13: 6MM, Incident Cases of Mantle Cell Lymphoma, Ages ?30 Years, Both Sexes, N, Selected Years 2013-2023 43
Table 14: 6MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N (Row %), 2013 44
Table 15: 6MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ?30 Years, N (Row %), 2013 46

1.2 List of Figures

Figure 1: 6MM, Incident Cases of Follicular Lymphoma, Ages ?30 Years, Both Sexes, N, 2013-2023 26
Figure 2: 6MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N, 2013 27
Figure 3: 6MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages ?30 Years, N, 2013 29
Figure 4: 6MM, Age-Standardized Incidence of Follicular Lymphoma (Cases per 100,000 Population), Ages ?30 Years, 2013 30
Figure 5: 6MM, Incident Cases of Marginal Zone Lymphoma, Ages ?30 Years, Both Sexes, N, 2013-2023 31
Figure 6: 6MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N, 2013 33
Figure 7: 6MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages ?30 Years, N, 2013 35
Figure 8: 6MM, Age-Standardized Incidence of Marginal Zone Lymphoma (Cases per 100,000 Population), Ages ?30 Years, 2013 36
Figure 9: 6MM, Incident Cases of DLBCL, Ages ?30 Years, Both Sexes, N, 2013-2023 37
Figure 10: 6MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N, 2013 39
Figure 11: 6MM, Sex-Specific Incident Cases of DLBCL, Ages ?30 Years, N, 2013 41
Figure 12: 6MM, Age-Standardized Incidence of DLBCL (Cases per 100,000 Population), Ages ?30 Years, 2013 42
Figure 13: 6MM, Incident Cases of Mantle Cell Lymphoma, Ages ?30 Years, Both Sexes, N, 2013-2023 43
Figure 14: 6MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N, 2013 45
Figure 15: 6MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages ?30 Years, N, 2013 46
Figure 16: 6MM, Age-Standardized Incidence of Mantle Cell Lymphoma (Cases per 100,000 Population), Ages ?30 Years, 2013 47

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.